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The integrity of the epidermis and mucosal epithelia
is highly dependent on resident self-renewing stem
cells, which makes them vulnerable to physical and
chemical insults compromising the repopulating
capacity of the epithelial stem cell compartment.
This is frequently the case in cancer patients re-
ceiving radiation or chemotherapy, many of whom
develop mucositis, a debilitating condition involving
painful and deep mucosal ulcerations. Here, we
show that inhibiting the mammalian target of rapa-
mycin (mTOR) with rapamycin increases the clono-
genic capacity of primary human oral keratinocytes
and their resident self-renewing cells by preventing
stem cell senescence. This protective effect of rapa-
mycin is mediated by the increase in expression
of mitochondrial superoxide dismutase (MnSOD),
and the consequent inhibition of ROS formation
and oxidative stress. mTOR inhibition also protects
from the loss of proliferative basal epithelial stem
cells upon ionizing radiation in vivo, thereby pre-
serving the integrity of the oral mucosa and protect-
ing from radiation-induced mucositis.
INTRODUCTION
Both epidermis and mucosal epithelia are highly dependent on
resident self-renewing stem cells, making them particularly
vulnerable to physical and chemical insults compromising the re-
populating capacity of the epithelial stem cell compartment. This
is often the case in cancer patients receiving radiation or chemo-
therapy, many of whom develop mucositis, a debilitating condi-
tion involving painful and deep mucosal ulcerations as a result of
damage to the normal tissue (Sonis, 2009, 2010). Mucositis
causes distress to the patients and results also in substantial
increase in per-patient care cost (Nonzee et al., 2008). Radio-
therapy is one of the most widely used cancer treatments
(Begg et al., 2011), and although technical advances now allowCell Sa more targeted delivery of radiation to the cancer cells, indirect
damage to the normal surrounding tissues still remains
a common and frequently weakening side effect (Citrin et al.,
2010). Hence, therapeutic interventions that can reduce the
deleterious effects of radiation on the normal epithelial stem cells
will have a great impact on the quality of life of cancer patients
and treatment outcome.
The mammalian target of rapamycin (mTOR) plays a central
role in the regulation of cell growth and cancer progression,
but paradoxically, increased mTOR activity can also cause
certain cells to undergo differentiation or senescence, thereby
exiting the proliferative cell pool (Castilho et al., 2009; Chen
et al., 2008; Lee et al., 2010; Liu et al., 2007; Zhang et al.,
2006; reviewed in Iglesias-Bartolome and Gutkind, 2011). In
particular, mTOR activation is one of the most frequent events
in human malignancies arising from the epithelial cells lining
the oral mucosa, tongue, and pharynx, collectively referred to
as head and neck squamous cell carcinomas (HNSCC) (Molinolo
et al., 2007). Inhibition of mTOR by the use of rapamycin and its
derivatives has shown promising antitumoral activity in a variety
of experimental models of HNSCC (Amornphimoltham et al.,
2005, 2008; Czerninski et al., 2009; Nathan et al., 2007) and in
recent clinical trials. While the clinical benefits of blocking
mTOR in HNSCC as a single agent are under current clinical
evaluation, we have asked whether mTOR inhibition with rapa-
mycin could synergize with the antitumoral effects of radiation,
one of the most frequent approaches for HNSCC treatment
(Delaney et al., 2005). We observed only a subtle increase in
the cytotoxic effect of ionizing radiation in a panel of HNSCC-
derived cells lines. Surprisingly, however, we found that mTOR
inhibition protects normal oral epithelial cells from ionizing-
radiation-induced epithelial stem cell depletion. Furthermore,
rapamycin also protected epithelial progenitor cells from replica-
tive senescence, extending dramatically their lifespan in vitro.
Emerging evidence suggest that this protective effect of mTOR
inhibition is mediated by the increased expression of mitochon-
drial superoxide dismutase (MnSOD), and the consequent
suppression of oxidative stress caused by the accumulation of
reactive oxygen species (ROS) in normal, but not in cancer, cells.
These observations prompted us to ask whether this differential
effect of rapamycin in normal and tumor epithelial cells could be
exploited to protect the oral mucosa against the deleterioustem Cell 11, 401–414, September 7, 2012 ª2012 Elsevier Inc. 401
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prevents the loss of proliferative epithelial progenitor stem cells
upon radiation and enhances their tissue repopulating capacity,
thereby preserving the integrity of the oral mucosa and protect-
ing from radiation-induced mucositis.
RESULTS
mTOR Inhibition Protects Primary Human Keratinocytes
from Loss of Clonogenic Capacity
Sensitization of cancer cells to the cytotoxic effect of radiation by
adjuvant therapy targeting oncogenic signaling circuitries may
represent a promising approach toward improving radiation
outcome (Begg et al., 2011). In this regard, activation of the
mTOR pathway has been recently recognized as a frequent
event driving neoplastic transformation, including HNSCC (Moli-
nolo et al., 2007), the sixth most prevalent cancer among men
worldwide (Parkin et al., 2005). Given that mTOR inhibitors can
sensitize other tumor types to radiation (Eshleman et al., 2002;
Konstantinidou et al., 2009; Murphy et al., 2009), we tested
whether mTOR blockade by rapamycin increases radiation-
induced cancer cell death in representative HNSCC cells lines.
Using HN12 and Cal27 cells as typical examples of HNSCC cells
that are highly sensitive to the antitumoral activity of rapamycin
(Amornphimoltham et al., 2005), however, we detected only
a limited synergistic effect on radiation-induced cell death
in vitro, as judged by the surviving fraction of cells exposed to
clinically relevant, sublethal doses of radiation in the presence
of rapamycin (Figures 1A and 1B; see scheme in Figure S1A
available online). The size of the colonies growing after radiation
was also not significantly affected by rapamycin, which com-
pletely inhibited mTOR activity as assessed by the phosphoryla-
tion of S6 (Figures 1A and 1B). Similar results were observed in
a large collection of HNSCC cells (not shown). Hence, these in-
vitro studies suggest that inhibition of mTOR in HNSCC cells
may only sensitize them slightly to radiation-induced cancer
cell death.
However, the impact of rapamycin treatment on normal
primary oral epithelial cells was quite remarkable. As a control
for the experiments using HNSCC cells, we evaluated the effect
of rapamycin on normal oral keratinocytes (NOKs). Simple
procedures are currently available to isolate primary human
NOKs that include cells with long-term self-renewal capacity,
as judged by their ability to support the prolonged survival of
corneal implants in humans (Chen et al., 2009; Nakamura
et al., 2007). Using similar procedures, we isolated NOKs from
gingival biopsies from healthy volunteers and confirmed that
these cultures lack fibroblast contamination (Figures S1B and
S1C). NOK cultures include epithelial stem cells exhibiting tissue
regenerative capacity, as judged by organotypic cocultures (Fig-
ure S1D) and by their ability to regenerate stratified epithelium
when grafted into nude mice (Figure S1E). Using the same radi-
ation treatment scheme as for HNSCC cells (Figure S1A), we did
not observe a decrease in the surviving fraction of NOKs under-
going rapamycin treatment (Figure 1C). On the contrary, rapamy-
cin significantly enhanced the colony size of NOKs compared
with vehicle-treated cells, and this increase wasmaintained after
radiation (Figures 1C and 1D). Along with the increase in colony
size, rapamycin also increased the colony forming efficiency of402 Cell Stem Cell 11, 401–414, September 7, 2012 ª2012 Elsevier Icontrol and irradiated human NOKs (Figure 1E). Since each large
colony is expected to grow from a single surviving self-renewing
epithelial stem cell (Jensen et al., 2010), these findings indicate
that rapamycin increases the survival and repopulating capacity
of epithelial progenitors, hence protecting from radiation-
induced loss of this tissue regenerative cell population. Inhibition
of mTOR can result in Akt activation due to the disruption of
a negative feedback loop in certain cellular systems (Zoncu
et al., 2011). Of interest, however, is that while mTOR activity
was completely inhibited by rapamycin in these cells, we did
not observe any effect on the phosphorylation levels of Akt after
rapamycin treatment (Figures 1C and 1F). This suggests that
the increased proliferative capacity of irradiated NOK cells
upon rapamycin exposure is unlikely related to an elevated Akt
activity, and hence to its prosurvival and growth promoting func-
tions (Manning and Cantley, 2007).
Rapamycin Decreases Senescence in Primary Human
Keratinocytes
To begin investigating the mechanisms underlying the higher re-
populating capacity of rapamycin-treated NOKs, we evaluated
different molecular events involved in apoptosis, senescence,
and differentiation. We could not observe significant differences
in the levels of p53 in NOKs after radiation exposure (Figure 2A),
nor in the number of apoptotic cells as judged by TdT-mediated
dUTP nick end labeling (TUNEL) assays (Figure 2B), indicating
that the activation of p53 and the elimination of severely
damaged cells by apoptotic death occurs normally after
irradiation in control and rapamycin-treated cells. An alternative
explanation for the enhanced clonogenic capacity of rapamycin-
treated human primary NOKs after radiation is that rapamycin
may induce cell quiescence, as radiation sensitivity can be
dependent on cell proliferation (Gudkov and Komarova, 2003).
However, rapamycin treatment reduced only slightly the prolifer-
ation of NOKs as judged by labeling of individual proliferating
cells by 5-ethynyl-20-deoxyuridine (EdU) staining (Figure S2).
This is aligned with the observation that rapamycin did not
prevent the apoptotic response to radiation, which reflects
a similar sensitivity to radiation-induced cell death in control
and rapamycin-treated cells. Thus, the differences in basal cell
proliferation may contribute to, but are unlikely to account for,
the increased clonogenic capacity of NOK after radiation upon
rapamycin treatment.
Interestingly, we found that rapamycin-treated NOKs exposed
to radiation show reduced levels of the DNA damage response
marker gH2AX at early and late time points (Figures 2C and
2D). This suggests that rapamycin treatment may reduce the
extent of DNA damage in NOKs (Bonner et al., 2008). The activa-
tion of the DNA damage response is one of themainmediators of
cell senescence, which results in irreversible growth arrest
(Kuilman et al., 2010; Rodier and Campisi, 2011). Accordingly,
we observed reduced levels of the senescence marker p16 in
rapamycin-treated NOKs after radiation (Figure 2E and 2F),
and also observed that rapamycin-treated cells show slightly
reduced levels of the differentiationmarker involucrin (Figure 2E).
These findings suggested the possibility that while rapamycin
may not protect from radiation-induced cell death, it might
instead prevent cells from entering senescence and terminal
differentiation by reducing DNA damage and the consequentnc.
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Figure 1. mTOR Inhibition Slightly Sensitizes HNSCC to Radiation-Induced Death but Protects Primary Human Keratinocytes from Loss of
Clonogenic Capacity
(A and B) Surviving fractions and individual colony areas from clonogenic assays of the HNSCC cell lines HN12 andCal27. mTOR activity is shown in control (Con)
or rapamycin (Rap)-treated cells by western blot of pS6 at 30 min and 24 hr after the indicated dose of radiation in grays (Gy).
(C) Surviving fractions and colony areas from clonogenic assays of human primary NOKs. mTOR inhibition is also shown by the levels of pS6 in western blot.
(D) Representative dishes from clonogenic assays of NOKs.
(E) Colony forming efficiency from clonogenic assays of human primary NOKs.
(F) Western blot analysis of NOKs treated with rapamycin for 72 hr. mTOR inhibition is shown by the levels of pS6 and the molecular weight shift of 4EBP. No
differences are seen in Akt phosphorylation at positions 308 (activating phosphorylation) and 473 (mTORC2 dependent). Means and standard errors (bars) from at
least three independent experiments are presented in graphs. See the Experimental Procedures section for experimental details. See also Figure S1.
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Figure 2. Rapamycin Decreases Senes-
cence in Primary Human Keratinocytes
(A) Western blot analysis of p53 expression in
irradiated control (Con) or rapamycin (Rap)-treated
human primary NOKs at 30 min and 24 hr after the
indicated dose of radiation in grays (Gy).
(B) TdT-mediated dUTP nick end labeling (TUNEL)
assay of NOK 24 hr after radiation exposure (8 Gy).
Bar: 100 mm.
(C) Western blot analysis of gH2AX levels in irra-
diated control (Con) or rapamycin (Rap)-treated
human primary NOKs. Quantification of three
independent experiments is also shown.
(D) Representative pictures of gH2AX (red) levels in
irradiated control and rapamycin-treated human
primary NOKs, counterstained to show nuclei
(blue) and actin (green). Bar: 20 mm.
(E and F) Western blot analysis of p16 levels in
irradiated control (Con) or rapamycin (Rap)-treated
human primary NOKs. Quantification of three
independent experiments is also shown.
(G) Proportion with respect to control cells
and representative pictures of NOKs positive
for senescence-associated b-galactosidase (SA-
bgal) 3 days after rapamycin treatment.
(H) Colony forming efficiency from clonogenic
assays of human primary NOKs transfected with
p16 siRNA. Insert shows western blot analysis of
p16 levels in NOKs transfected with control siRNA
(siRNACon) or siRNA for p16. Means and standard
errors (bars) from at least three independent
experiments are presented in graphs. See also
Figure S2.
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capacity. To test this hypothesis, we measured the percentage
of cells positive for senescence-associated beta-galactosidase
(SA-bgal), a known marker of senescent cells (Debacq-
Chainiaux et al., 2009). Compared with control cells, rapamycin
treatment reduced the accumulation of senescent cells in both
control and irradiated cells (Figure 2G). The activation of the reti-
noblastoma protein (RB) tumor suppressive pathway by the
accumulation of p16 is often considered a key mechanism
triggering cell senescence in several systems, including skin
keratinocytes (Kuilman et al., 2010; Luis et al., 2011). Indeed,
knockdown of p16 in NOKs (Figure 2H, insert) resulted in a signif-
icant increase in the colony forming efficiency of NOKs under404 Cell Stem Cell 11, 401–414, September 7, 2012 ª2012 Elsevier Inc.control conditions and after ionizing radi-
ation (Figure 2H). Together, these findings
suggest that mTOR inhibition may in-
crease the clonal proliferative capacity
of oral epithelial stem cells by preventing
the activation of specific cell senescence
mechanisms.
Rapamycin Prolongs the Lifespan
of NOK Cultures by Limiting
Epithelial StemCell Exhaustion due
to Replicative Senescence
Based on these results, we next asked
if mTOR inhibition would also protectNOKs from replicative senescence, a process that involves the
progressive depletion of progenitor cells due to senescence
and differentiation, and often serves as an in vitro surrogate for
aging (Zeng, 2007). Surprisingly, continuous treatment of human
primary NOKs with rapamycin extended dramatically the life-
span of the cells in culture (Figure 3A). Specifically, rapamycin-
treated cells almost tripled their lifespan and total cumulative
population doublings when compared to control cells (Figures
3B–3D). We can estimate that while in the absence of rapamycin
a single cell will give rise approximately to 106 cells before under-
going senescence, while in the presence of rapamycin a single
cell will give rise to around 1017 cells. Similar results were
observed in multiple independent NOK isolates. This effect
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mTOR Inhibition Protects from Mucositiswas mediated by the continuous inhibition of mTOR, as cells
quickly undergo replicative senescence after rapamycin removal
(Figure 3E).
Western blot analysis revealed that cells continued to respond
to rapamycin along the entire treatment, as assessed by the
inhibition of phosphorylation of S6 by rapamycin (Figure 3F).
While we did not observe significant changes in the phosphory-
lation status of Akt (Figure 3F), there was a clear reduction in the
levels of p16 in rapamycin-treated NOKs when compared to the
increasing p16 expression levels with time in control cells (Fig-
ure 3F), concomitant with a massive increase in SA-bgal in
control cells, but not in rapamycin-treated cells (Figure 3G). As
replicative senescence involves the progressive depletion of
progenitor cells in primary cultures, we analyzed the effects of
rapamycin treatment on the levels of the epithelial stem cell
marker p63 (Blanpain and Fuchs, 2009). As shown if Figure 3F,
we observed that rapamycin prevented the disappearance of
the epithelial progenitor marker p63, indicating that mTOR
inhibition reduces the depletion of stem cells from the culture.
These results highlight the possibility that mTOR inhibition may
increase the proliferative capacity of human primary NOKs by
preventing the senescence of their repopulating stem cells.
Senescent cells acquire the ability to secrete a variety
of cytokines, often referred to as the senescence-associated
secretory phenotype (SASP). These secreted cytokines have
myriad effects on neighboring cells, including the promotion of
growth arrest and senescence (Acosta et al., 2008; Coppe´
et al., 2008; Rodier and Campisi, 2011). This prosenescence
autocrine/paracrine positive feedback loop can aid in the accel-
erated depletion of repopulating cells from tissues and primary
cultures. As shown in Figure 3H, rapamycin significantly reduced
the secretion of most senescence-associated cytokines, an
effect that in turn may contribute to the retention of the prolifer-
ative capacity of rapamycin-treated primary epithelial cells.
Rapamycin Protects from Oxidative Stress through
Increased MnSOD Expression
In search of the potential mechanisms mediating the protective
effect of mTOR inhibition in epithelial stem cell senescence, we
explored whether rapamycin treatment of NOKs results in the
activation of molecular events often associated with delayed
aging. After applying rapamycin treatment, however, we did
not observe an increase in the expression, nuclear localization,
or transcriptional activation of FoxO proteins, or changes in the
expression of SIRT family members, all of which have been
shown to influence lifespan and stem cell response to stress
(Calnan and Brunet, 2008; Finkel et al., 2009) (not shown). On
the other hand, ROS can mediate the deleterious effects of
radiation and contribute to DNA damage and the activation of
senescence pathways in cells (Diehn et al., 2009; Kuilman
et al., 2010; Sonis, 2009; Spitz et al., 2004). By analyzing the
levels of ROS by DHE staining, we found that rapamycin treat-
ment prevented the induction of ROS after radiation in primary
NOKs, while it failed to protect from ROS accumulation in
HNSCC cells (Figure 4A). Furthermore, rapamycin prevented
the remarkable increase both in ROS preceding NOK cell growth
arrest (Figure 4A, 10 days) and in cells undergoing replicative
senescence (Figure 4A, 40 days). These observations suggested
that mTOR inhibition might limit the accumulation of ROS inCell SNOKs by decreasing ROS formation or by accelerating their
inactivation. Regarding the latter, we hypothesized that if the
protective effects of rapamycin are mediated by an increase in
the cellular ROS scavenging capacity, mTOR inhibition should
also protect from hydrogen peroxide (H2O2)-induced senes-
cence. Indeed, pretreatment of primary NOKs with rapamycin
prevented the appearance of the DNA damage marker gH2AX
and the expression of the senescence marker p16 following
H2O2 treatment (Figure 4B), while it did not prevent the increase
in DNA damage in HNSCC cells (Figure 4C). These results further
supported the possibility that rapamycin may prevent normal
cells from entering senescence and increase their replicative
capacity by suppressing ROS accumulation, and hence oxida-
tive stress.
Rapamycin treatment did not induce significant changes in
the ratio of reduced/oxidized glutathione (GSH) (Figure S3A),
indicating that this might not be the mechanism by which
mTOR inhibition scavenges ROS. We next measured the levels
of different enzymes involved in the detoxification of ROS. Inter-
estingly, among these, rapamycin treatment did not affect
the expression of catalase or cytosolic superoxide dismutase
(Cu-ZnSOD), but specifically increased the protein levels of
MnSOD, the mitochondrial-localized superoxide dismutase, in
NOKs, but not in HN12, cells (Figures 4D and 4E). Of direct rele-
vance to our studies, MnSOD has been linked to radiation
resistance, and its deficiency can promote the appearance of
accelerated aging phenotypes (Hosoki et al., 2012; Velarde
et al., 2012; Weyemi et al., 2012). Accordingly, MnSOD knock-
down in NOK increased the basal levels of p16 expression and
DNA damage as measured by gH2AX, and this effect could
only be partially rescued by rapamycin (Figure 4F). Furthermore,
decreased expression of MnSOD abrogated the increased
clonogenic capacity of rapamycin-treated NOKs under normal
conditions and after radiation (Figure 4G). Interestingly, mTOR
inhibition did not increase the mRNA levels of MnSOD (Fig-
ure S3B), indicating that translational or postranslational mecha-
nisms rather than transcriptional events may account for the
increased MnSOD protein expression caused by rapamycin in
NOKs. In particular, MnSOD activity and stability are highly
regulated by posttranslational modifications, including protein
acetylation in the mitochondria (Takahashi et al., 2011; Tao
et al., 2010). Indeed, the amount of both total and acetylated
MnSOD increased upon rapamycin treatment in human NOKs
(Figure S3C).
mTOR Inhibition Prevents the Deleterious Effects
of Radiation in Normal Oral Epithelia In Vivo
Considering the remarkable effects of mTOR inhibition in vitro,
we next asked if rapamycin could rescue the deleterious effects
of ionizing radiation in normal oral epithelia. For these experi-
ments, 8-week-old C3H mice received fractionated radiation of
a 6 grays (Gy) dose/day/mouse for 5 days and, before each radi-
ation dose, mice were injected with vehicle (control) or rapamy-
cin (Figure 5A). Mice were euthanized at day 5, 1 hr after the last
dose of radiation, and at day 10, 5 days after the last radiation
dose. Tongues were removed and processed for analysis to
examine the immediate impact of radiation and its long term
effects, as applicable. In control animals, mTOR activity is
restricted to the upper, more differentiated and nonproliferativetem Cell 11, 401–414, September 7, 2012 ª2012 Elsevier Inc. 405
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Figure 3. Rapamycin Prolongs the Lifespan of NOK Cultures
(A) Cumulative population doubling from a representative culture of primary NOKs in control conditions or in the continuous presence of rapamycin. Each dot
represents a passage and dotted line indicates that cells could not be further expanded.
(B and C) Average of the days before replicative senescence and themaximum cumulative population doublings from three different cultures of NOKs cultured in
control conditions (Con) or in the continuous presence of rapamycin (Rap).
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ported to be the case in the skin (Squarize et al., 2010). Five
days of radiation (day 5) did not result in an increase in mTOR
activity in vehicle-treated animals as judged by phosphorylation
of S6 (Figure 5B). However, we could observe aberrant activation
of mTOR throughout the basal layer of the tongue epithelium
5 days after the last dose of radiation (day 10), which was pre-
vented by rapamycin treatment during the radiation period (Fig-
ure 5B). Surprisingly, mTOR inactivation by rapamycin concom-
itant with radiation almost completely prevented the appearance
of mucositis/ulcers in irradiated mice (Figure 5C). Histological
analysis of the tongues revealed the preservation of the epithelial
layer in irradiated rapamycin-treated mice, although radiation-
associated tissue changes were observed (Figure 5D). No differ-
ences were observed in response to rapamycin in nonirradiated
mice (Figure S4A). In contrast, extensive ulceration, up to 50%of
the surface of the tongue, was evident in the animals treated with
vehicle, which was absent in all rapamycin-treated mice (Fig-
ure 5D). Interestingly, rapamycin did not protect from mucositis
when mice were irradiated with high intensity in a single dose
(15 Gy, Figures S4B and S4C), indicating that the protection
conferred by rapamycin treatment might only be effective at
clinically relevant fractionated radiation doses.
Rapamycin Treatment Prevents the Loss of Proliferative
Capacity of the Epithelial Stem Cell Compartment after
Radiation In Vivo
Aligned with our in vitro results, we did not observe substantial
differences between control and rapamycin-treated mice in the
visible accumulation of p53 in basal epithelial cells after radiation
(Figure 6A). However, we observed a remarkable reduction in the
levels of gH2AX and increased levels of MnSOD (Figure 6A), indi-
cating that rapamycin may protect normal epithelial cells from
DNA damage and oxidative stress in vivo. Indeed, aligned with
this possibility, we have recently shown that the persistent acti-
vation of mTOR by Wnt1 leads to the accumulation of DNA
damage and accelerated epithelial stem cell senescence, which
can be prevented by rapamycin treatment (Castilho et al., 2009;
Liu et al., 2007). Hence, our in vitro and in vivo observations
suggest the possibility that rapamycin might protect from radia-
tion-induced depletion of epithelial progenitors due to senes-
cence or terminal differentiation, thereby increasing their survival
and repopulating capacity. This prompted us to analyze the
presence of the basal stem cell marker p63 (Pellegrini et al.,
2001) in mice exposed to radiation and treated with rapamycin
or vehicle. As shown in Figure 6B, we found that rapamycin pre-
vented the radiation-induced disappearance of the epithelial
progenitor marker p63 and the basal cell marker cytokeratin 5
(Blanpain and Fuchs, 2009). Furthermore, by using the prolifera-
tion marker Ki-67, we found that rapamycin prevented also the(D) Bright field images of NOKs treated or not with rapamycin for 15 or 45 days.
(E) Cumulative population doubling from a representative culture of primary NOKs
42 days. Each dot represents a passage and dotted line indicates that cells cou
(F) Western blot analysis of NOKs treated (Rap) or not (Con) with rapamycin for 1
differences were seen in Akt phosphorylation at positions 308 and 473. p16 and
(G) Staining for SA-bgal 35 days after rapamycin treatment.
(H) Accumulation of different cytokines associated with the senescence secreto
(control) with rapamycin expressed as fold change. See the Experimental Procedu
from at least three independent experiments are presented in graphs in (B), (C),
Cell Sradiation-induced block in proliferation of the basal progenitor
layer of the oral epithelia at the end of the radiation regime,
and preserved the proliferative and tissue repopulating function
of the basal epithelial cells 5 days after the last radiation dose
(Figure 6B). Rapamycin treatment in nonirradiated mice did not
affect the number and distribution pattern of p63 positive cells
(not shown); we only observed a slight and yet significant
increase in the levels of p63 expression in basal progenitor cells
upon rapamycin treatment (Figure S5). Taken together, our
observations indicate that rapamycin treatment prevents the
loss of proliferative capacity of the epithelial progenitor and
stem cell compartment after radiation, which in turn protects
from epithelial stem cell depletion and the consequent appear-
ance of widespread ulcers and mucositis.
DISCUSSION
While emerging evidence supports the central role of the mTOR
pathway in cell growth and cancer progression, increased
mTOR activity paradoxically can also cause cells to undergo
differentiation or senescence, thereby exiting the proliferative
cell pool (reviewed in Iglesias-Bartolome and Gutkind, 2011). In
this context, we have recently shown that the persistent activa-
tion of mTOR by Wnt1 leads to accelerated epithelial stem cell
senescence and premature aging in mice (Castilho et al., 2009;
Liu et al., 2007). Here, we show that mTOR inhibition decreases
epithelial stem cell depletion. Our results indicate that rapamycin
prevents cells from entering senescence and terminal differen-
tiation programs during replicative senescence or when ex-
posed to radiation-induced stress conditions, without protecting
HNSCC cells from radiation-induced cell death.
Senescence can be triggered by multiple mechanisms,
including those resulting in ROS production and oxidative stress
(Kuilman et al., 2010; Rodier and Campisi, 2011). The generation
of ROS is also an important mediator of the cellular alterations
caused by radiation exposure (Diehn et al., 2009; Sonis, 2009;
Spitz et al., 2004), including mucositis (Citrin et al., 2010; Cotrim
et al., 2005, 2007). Our results show that mTOR inhibition causes
a remarkable reduction in ROS accumulation in irradiated NOKs
as well as in NOKs undergoing replicative senescence, thus sug-
gesting that inhibition of ROS formationmay represent one the of
mechanisms by which rapamycin protects from cell senescence
and stem cell depletion. Consistent with this possibility, mTOR
inhibition by rapamycin prevented the appearance of DNA
damage and the expression of the senescence marker p16 after
the direct exposure of human primary NOKs to H2O2-induced
oxidative stress.
In this regard, a reduction in ROS formation after mTOR
blockade has been documented in Drosophila cells and human
T cells, albeit by a yet to be determined molecular mechanismBar: 100 mm.
in which rapamycin treatment was withdrawn (Rap removal) or kept (Rap) after
ld not be further expanded.
5 or 35 days. mTOR inhibition is reflected by the levels of pS6. No consistent
p63 levels were reduced or preserved, respectively, by rapamycin treatment.
ry phenotype in conditioned media from human primary NOKs treated or not
res section for cytokine concentration levels. Means and standard errors (bars)
and (H).
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Figure 4. Rapamycin Protects from Oxidative Stress through Increased MnSOD Expression
(A) Analysis of reactive oxygen species (ROS) levels by Dihydroethidium (hydroethidine) (DHE) staining 24 hr after radiation in NOK and HN12 cells pretreated or
not (control) with rapamycin (upper panel), and FACS analysis of ROS levels by DHE staining in NOKs after 10 or 40 days of continuous rapamycin treatment
(lower panel).
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mTOR Inhibition Protects from Mucositis(Lee et al., 2010; Schieke et al., 2006). Here, we observed that
ROS inhibition by rapamycin correlated with increased levels
of MnSOD. MnSOD is the main ROS scavenger in the inner mito-
chondrial matrix, and acts as the first line of defense against
mitochondrial oxidative damage (Holley et al., 2011). Further-
more, we obtained evidence that increased MnSOD mediates
the beneficial effects of mTOR inhibition in primary human
NOKs. Indeed, MnSOD knockdown reverted the decrease in
p16 expression and the protective effects of rapamycin in NOK
clonogenic capacity under basal conditions and after radiation
exposure. Consistent with a protective role of MnSOD, its
targeted deletion in connective tissue results in reduced lifespan
that correlates with an increase in cell senescence due to the
expression of p16 (Treiber et al., 2011). Moreover, mitochondrial
oxidative stress resulting from MnSOD deficiency results in
cellular senescence in mouse skin, a process associated with
increased nuclear DNA damage (Velarde et al., 2012). The pre-
cise mechanism by which mTOR blockade results in increased
MnSOD protein expression is at present not known. Rapamycin
treatment did not increase mRNA levels of MnSOD, indicating
that its enhanced protein expression may result from increased
translation or yet to be identified postranslational events, such
as enhanced protein stability. We observed that rapamycin
promotes an increase in both total and acetylated forms of
MnSOD, indicating that rapamycin may affect the stability of
MnSOD through changes in acetylation of the enzyme. These,
as well as other possibilities, warrant further investigation.
Rapamycin treatment onmice was effective at limiting the loss
of proliferative basal oral epithelial stem cells upon irradiation,
thereby enhancing their tissue repopulating capacity and pre-
venting the appearance of ulcers. Aligned with our observations
supporting the fact that increased MnSOD levels prevent cell
senescence in human primary NOKs, this protective effect of
mTOR inhibition involved increased expression of MnSOD in
the basal progenitor epithelial cell layer. Thus, these results raise
the possibility that by increasing the expression of MnSOD,
mTOR inhibitors may reduce ROS-induced DNA damage, oxida-
tive stress, and ultimately epithelial stem cell senescence, pro-
tecting from radiation-induced depletion of tissue-repopulating
stem cells and the concomitant appearance of ulcers andmuco-
sitis (Figure S6). On the other hand, rapamycin decreased the
release of multiple senescence-associated cytokines, suggest-
ing that mTOR inhibition might also ameliorative mucositis by
preventing the release of a prosenescent and proinflammatory
secretome from normal and irradiated cells (Sonis, 2009).
While mTOR inhibition by rapamycin protects normal cells
from initiating senescence programs, intriguingly, rapamycin(B) Western blot of senescence (p16) and DNA damage (gH2AX) marker levels af
(C) Western blot of DNA damage (gH2AX) marker levels after 24 hr of H2O2 treat
(D) Western blot analysis of protein levels of ROS scavenging enzymes (MnSOD
treatment. mTOR inhibition by rapamycin is shown by the levels of pS6.
(E) Quantification of MnSOD protein expression levels by western blot in NOK an
(F) Western blot analysis of p16 and gH2AX levels in control (Con) or rapamycin
siRNA targeted against MnSOD (siMnSOD).
(G) Western blot analysis of MnSOD expression and colony forming efficiency fro
(siCon) or siRNA targeted against MnSOD (siMnSOD). Cells were pretreated or not
grays (Gy), and 24 hr later were subjected to clonogenic assays. Means and stand
graphs. See also Figure S3.
Cell Sdoes not increase the viability or survival of HNSCC cells. This
is aligned with the inability of rapamycin to increase MnSOD in
these cells, which highlights the fact that signaling pathways
and stress responses are often differentially wired in normal
and cancer cells. HNSCC arises from multiple genetic and
epigenetic alterations, and among them, loss of heterozygosity
in the p16 locus concomitant with the inability to express the
remaining allele due to p16 promoter methylation is one of the
earliest events in HNSCC progression (Rosas et al., 2001).
Approximately 20% of all HNSCC cases are also now known
to be associated with HPV16 infection (zur Hausen, 2009). While
the E6 HPV oncogene promotes p53 degradation, the E7 HPV
oncogene binds and inhibits RB, thereby rendering p16 unable
to stimulate its tumor suppressive functions (Moody and
Laimins, 2010). Thus, p16 inactivation by genetic and epigenetic
events or by viral oncogenes is a shared feature in most HNSCC
lesions, which therefore rendersmTOR inhibitors unable to affect
p16 expression or function in these cells. This could in turn help
explain why rapamycin exposure does not have any impact on
the activation of p16-dependent cell senescence pathways in
HNSCC.
The demise of stem cells by senescence or differentiation in
response to extrinsic or intrinsic cellular stress pathways may
represent a key mechanism driving stem cell depletion, thereby
contributing to reduced tissue regenerative capacity. In this
regard, our results highlight the importance of tissue renewal
mediated by adult stem cells in organs that are continuously
exposed to environmental assaults, and demonstrate that the
aberrant activation of the mTOR pathway plays a predominant
role mediating the depletion of the epithelial stem cell compart-
ment. Furthermore, our results support the likely contribution of
mitochondrial oxidative damage to mTOR-dependent cellular
senescence in adult tissue-regenerating cells. On the other
hand, loss of proliferative and repopulating activity of normal
epithelial stem cells is an undesired secondary effect of most
antineoplastic treatments. In the oral mucosa, this process, in
conjunction with other factors, can lead to mucositis, a mucosal
injury characterized by disruption of epithelial integrity, ulcera-
tion, and pain (Sonis, 2009, 2010). As radiotherapy is one of
the most widely used antineoplastic treatments, accounting for
treatment of almost 80% of patients with head and neck cancer
(Delaney et al., 2005), interventional strategies reducing the dele-
terious effect of radiation on normal epithelia and hence pre-
serving the integrity of the oral mucosa will have a great impact
in the quality of life of cancer patients (Citrin et al., 2010). Ulti-
mately, our findings indicate that by preserving the tissue repo-
pulating capacity of the epithelial stem cells, mTOR inhibitionter 24 hr of H2O2 treatment in NOKs pretreated or not (control) with rapamycin.
ment in the HNSCC HN12 cells pretreated or not (control) with rapamycin.
, Cu-ZnSOD, and catalase) in NOKs and HN12 cells after 72 hr of rapamycin
d HN12 cells after 72 hr of rapamycin treatment.
(Rap)-treated human primary NOKs transfected with control siRNA (siCon) or
m clonogenic assays of human primary NOKs transfected with control siRNA
(control) with rapamycin for 72 hr after siRNA transfection, irradiated with 0 or 3
ard errors (bars) from at least three independent experiments are presented in
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Figure 5. Rapamycin Prevents the Deleterious Effects of Radiation in Normal Oral Epithelia In Vivo
(A) Fractionated radiation and drug treatment scheme for mice.
(B) Representative pictures of pS6 staining (red) in control (nonirradiated) animals and irradiated animals at the end of the radiation period (day 5) or 5 days after
the last radiation dose (day 10), after they had received vehicle (radiation) or rapamycin (radiation+rapamycin). Tissues were counterstained to label actin (green)
and nuclei (blue). Right panels show details at higher magnification. Location of the basal membrane is indicated with a white dotted line. Bar: 100 mm.
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mTOR Inhibition Protects from Mucositiswith rapamycin and newly developed agents (Wander et al.,
2011) may prevent the appearance of radiation-inducedmucosi-
tis and its consequent negative impact on anticancer treatment
outcome and cost.
EXPERIMENTAL PROCEDURES
Cell Culture
NOK isolation and culture was performed as described (Leelahavanichkul and
Gutkind, 2012). NOKs were maintained in defined keratinocyte serum free
media (KSFM) (Invitrogen) supplemented with antibiotics at 37C in the
presence of 5% CO2 and passed every 3–4 days. NOKs between passages
two to four were used for the experiments. HN12 and Cal27 have been
described previously (Amornphimoltham et al., 2005). Detailed methods for
NOK isolation and cell culture are described in the Supplemental Experimental
Procedures.
Irradiation and Clonogenic Assays
Surviving fractionwas calculated as previously described (Franken et al., 2006)
relative to the respective nonirradiated cells. Colonies were counted and
measured with calibrated images in ImageJ. Colony forming efficiency was
expressed as the proportion of plated cells that formed colonies relative to
the number of colonies formed by nonirradiated control cells.
Immunoblot Analysis and Cytokine Measurements
Cells were lysed in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA,
1% Nonidet P-40) supplemented with protease (protease inhibitor cocktail,
Sigma) and phosphatase inhibitors (1 mM Na3VO4 and 1 mM NaF). Equal
amounts of total cell lysate proteins were subjected to SDS-polyacrylamide
gel electrophoresis. Bands were detected by using near-infrared fluorescence
(Odyssey LI-COR Biotechnology). Cytokines were analyzed in conditioned
media by the Cytokine Core Laboratory, University of Maryland, using the
Luminex Multianalyte System. Values of cytokines were corrected to the
protein and expressed as percentage of the control.
Cell Proliferation, Apoptosis, and Senescence
Cell proliferation was evaluated using incorporation of EdU with the Click-iT
software, apoptosis was detected using the Click-iT TUNEL Alexa Fluor 594
Imaging Assay (Invitrogen), and SA-bgal activity was measured using the
SA-bgal kit (Cell Signaling Technology) according to the manufacturer’s
instructions. The proportion of positive cells was determined by fluo-
rescence or transmissionmicroscopy and quantified using ImageJ. Population
doublings were calculated as previously described (Cristofalo et al., 1998).
ROS Measurement and Immunofluorescence
ROS measurement was performed by FACS in cells incubated with
Dihydroethidium (hydroethidine) (Molecular Probes) at a final concentration
of 1.5 mM for 10 min at 37C. For immunofluorescence, cells and tissues
(cryosections) were fixed with 3.2% paraformaldehyde in PBS and permeabi-
lized with Triton X-100 0.1% in glycine 200 mM in PBS. Nonspecific binding
was blocked with 3%of bovine serum albumin (BSA) or 10%FBS in PBS. Cells
and tissues were incubated with the primary antibodies overnight at 4C,
followed by 1.5 hr incubation with the secondary antibodies. Nuclei were
stained with Hoechst 33342 (1:2,000, Invitrogen) and actin with Alexa 546
phalloidin (Invitrogen) according to the manufacturers’ instructions. Images
were taken using a Zeiss Axio Imager Z1 microscope equipped with an(C) Representative pictures and quantification of tongues stained with toluidine bl
had received vehicle (Radiation) or rapamycin (Radiation+Rapamycin). Lack of p
royal blue staining in epithelium defects. Quantification represents mean and
experiments.
(D) Histological analysis of the tongues from control (nonirradiated) animals and
received vehicle (radiation) or rapamycin (radiation+rapamycin). Small panels sho
and ventral epithelial morphology. Epithelial layer is preserved in irradiated rapamy
changes are evident. Ulcerations, up to 50% of the surface of the tongue, and rad
vehicle. An ulcerated and nonulcerated area is magnified. See also Figure S4.
Cell SApotome device (Carl Zeiss) and a motorized stage. Detailed protocols and
image quantification procedures are described in the Supplemental Experi-
mental Procedures.
Animal Irradiation
Female C3H mice were used for this study. The head and neck area was
irradiated by placing each animal in a specially built Lucite jig. For fractionated
radiation, mice were injected intraperitoneally every day for 5 days with
rapamycin (5 mg/kg) and irradiated at 6 Gy/day. Ionizing radiation was deliv-
ered with a Therapax DXT300 X-ray irradiator (Precision X-ray) at a dose rate
of 1.9 Gy/min. Result corresponds to six animals and is representative of
three independent experiments. Detailed methods are described in the
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes six figures and
Supplemental Experimental Procedures and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2012.06.007.
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